ProCE Banner Activity

CME

Research Focus: Achieving Hemostatic Balance in Hemophilia With Emerging Therapies

Text Module

In this interactive text module, global experts provide an overview of the evolving treatment landscape of hemophilia, including novel agents for rebalancing homeostasis, best practices for integrating these agents into clinical practice, and how to address common barriers to care and patient adherence. 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 21, 2024

Expiration: March 20, 2025

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Margareth C. Ozelo

Margareth C. Ozelo, MD, PhD

Professor of Hematology and Transfusion Medicine
Department of Internal Medicine - School of Medical Sciences UNICAMP
Director of Hematology Division, Hemocentro UNICAMP, University of Campinas
University of Campinas
Campinas, Sao Paulo, Brazil

Runhui Wu

Runhui Wu, MD, PhD

Hemophilia Comprehensive Care Center
Hematology Center
National Center for Children’s Health, China
Beijing Children’s Hospital, Capital Medical University
Beijing, China

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Target Audience

This program is intended for hematologists and other healthcare professionals to care for patients with hemophilia.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and confidence of learners to integrate novel and emerging therapies in the treatment of appropriate patients with hemophilia A or B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise the engineered mechanism by which new therapies for hemophilia A and B can restore hemostatic balance

  • Evaluate the available data for investigational nonfactor therapies for hemophilia and their ability to improve patient outcomes without introducing new health risks

  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available

Faculty Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD: consultant/advisor/speaker: Bayer, BioMarin, CSL Behring, HEMA Biologics, LFB, Magellan, Novo Nordisk, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda.

Margareth C. Ozelo, MD, PhD

Professor of Hematology and Transfusion Medicine
Department of Internal Medicine - School of Medical Sciences UNICAMP
Director of Hematology Division, Hemocentro UNICAMP, University of Campinas
University of Campinas
Campinas, Sao Paulo, Brazil

Margareth C. Ozelo, MD, PhD: researcher: Bayer, BioMarin, Pfizer, Roche, Sanofi, Takeda; consultant/advisor/speaker: BioMarin, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda.

Runhui Wu, MD, PhD

Hemophilia Comprehensive Care Center
Hematology Center
National Center for Children’s Health, China
Beijing Children’s Hospital, Capital Medical University
Beijing, China

Runhui Wu, MD, PhD: researcher: Bayer-China, Sinocelltech Group Limited; consultant/speaker: Bayer, Novo Nordisk, Pfizer, Roche, Sanofi, Sinocelltech Group Limited, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 21, 2024, through March 20, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.